- Conditions
- Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification
- Interventions
- Nivolumab, Capecitabine, Oxaliplatin
- Drug
- Lead sponsor
- Kidney Cancer Research Bureau
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced May 21, 2026, 10:10 PM EDT